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Summary We report on a case of an adult patient treated for rheumatoid arthritis
with infliximab, a chimerical monoclonal antibody to TNFa. Apart from this, the
patient also showed clinical signs of obstructive sleep apnea syndrome that was
confirmed by polysomnographic study. After infliximab treatment, additional sleep
studies revealed an increase in the number of apneic events and SaO2 dips suggesting
that TNFa plays an important role in the pathophysiology of sleep apnea. Thus,
clinical recognition of sleep disordered breathing should be taken into account when
rheumatoid arthritis patients are to be treated with infliximab.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Tumour necrosis factor-a (TNFa) is a cytokine that
plays an important role in the pathogenesis of
rheumatoid arthritis (RA), and blocking strategies.1
In patients with long standing RA and high disease
activity despite conventional treatment, inflixi-
mab, a chimerical monoclonal antibody to TNFa,
has been shown to be clinically effective.2
TNFa is also involved in sleep regulation3 as well
as in the pathogenesis of obstructive sleep apnea
(OSA).4–6 Therefore, the use of TNFa antibodies
may help define the role of cytokines in OSA.
We report on a case of an adult patient with RA
and who was treated with infliximab. The patient
also had a condition of OSA and the result of the
infliximab treatment was an increased number of
apneic events and SaO2 dips.
Case report
A 62-year-old woman was referred to the Rheuma-
tology Division for treatment with infliximab. She
had a 19-year-history of RA, according to the
standard criteria.7 Cervical spine radiographs
showed no evidence of significant atlantoaxial
subluxation. The patient reported frequent noctur-
nal awakenings with a sensation of choking,
snoring, unrefreshing sleep, daytime sleepiness
and fatigue for 2 years. Her Epworth sleepiness
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score was abnormal. Physical examination showed
obesity (BMI¼ 31 kg/m2), severe deforming arthri-
tis of multiple joints with no active synovitis, and
absence of dental malocclusion.
Two polysomnographic studies were carried out
and the diagnosis of OSA was confirmed (Table 1).
Afterwards, infliximab (3mg/kg of body weight)
was applied normally as a treatment for the RA.
Additional sleep studies were performed revealing
a clear worsening of the condition after the
application of infliximab. There was an increase in
obstructive apneas and hypopneas, as well as
oxygen desaturation index (SaO2 dips), and a
worsening of the sleep oxymetric pattern; on the
other hand, the number arousal decreased (Fig. 1,
Table 1). In response to this, overnight continuous
positive airway pressure (CPAP) was started and
infliximab treatment was maintained which re-
sulted in the elimination of the respiratory events.
Discussion
In RA patients, sleep apnea can be caused by
narrowing of upper airway, either by changes in the
temporomandibular joints and the position of
cervical vertebrae.8 In our case, however, clinical
and radiological examination did not show these
disturbances. Therefore, it is our opinion that this
patient presented both RA and sleep apnea coin-
cidentally, that is, the diseases were not asso-
ciated. The infliximab treatment for RA may have
worsened an already existing OSA, as evidenced by
the increased number of apneic events and SaO2
dips after infliximab treatment. Polysomnographic
studies indicated no changes in body position or
sleep stages before and after infliximab treatment.
The reasons why infliximab worsens the
apneas and SaO2 dips in our OSA patient while
improving arousals remains obscure but a hypoth-
esis which involves the role of TNFa to explain this
seemingly contradictory finding can be advanced.
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Table 1 Sleep parameters before (Days 1 and 2) and during treatment with infliximab (Day 3).
Before treatment After treatment
Day 1 Day 2 Day 3
Total sleep time (min) 396 419 346
Sleep efficiency (%) 67 84 80
Sleep latency (min) 24 30 27
Stages Iþ II (%) 80 78 88
Stages IIIþ IV (%) 16 11 6
Stage REM (%) 4 11 6
Arousals/h 14 17 4
Mean SaO2 (%) 88 91 86
Minimum SaO2 (%) 70 81 52
ODI4 59 46 198
Mean heart rate (bpm) 72 69 64
Obstructive apnea count 54 137 212
Hypopnea count 226 196 175
AHI 47 49 74
ODI4: (oxygen desaturation index, indicates events with falls of SaO2X4% per night); Mean SaO2 (%): Mean SaO2 during
desaturation during the recording; Minimun SaO2 (%): Minimun SaO2 during the recording; AHI: Apnea hipopnea index.
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Figure 1 Two trends of SaO2 before (a) and after
infliximab treatment (b). After infliximab treatment the
oximetric pattern shows greater desaturations.
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The worsening of OSA can be associated to the
effect of TNFa on leptin. Finck et al.9 have shown
that TNFa induces leptin production. Also, leptin
circulating levels have been shown to be positively
correlated with apnea–hipopnea index and TNFa6
and leptin levels decrease after CPAP treatment.10
Therefore, it is possible that blocking TNFa with
infliximab reduces leptin and that this leptin
deficiency plays a role in the major desaturations
experienced by OSA patients.11,12 On the other
hand, in OSA patients some authors have shown
that TNFa is positively correlated with the degree
of hypoxia and the degree of nocturnal sleep
disturbance and may mediate the daytime sleepi-
ness associated with this disorder, independent of
obesity.5,6 Moreover, in patients with RA and
elevated circulating levels of TNFa,13 sleep frag-
mentation and frequent arousals with marked
disruption of sleep continuity can occur.14 Thus,
TNFa seems to be involved in sleep fragmentation
and arousibility. It is known that TNFa may signal
the central nervous system via vagal afferents15
and vagus nerve stimulation may influence respira-
tion via central projections to the reticular forma-
tion of the medulla or medial pons.16 By interfering
with this mechanism, the anti-TNFa treatment may
decrease the arousal response to the obstructive
episode. Unfortunately, measurements of leptin
and TNF were not made for our patient and, thus,
this hypothesis cannot yet be confirmed.
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